

**In the Claims**


α Please amend the claims as follows: 6

- aa1
- 56620755-102999
5. (amended) The amphiphilic drug-oligomer conjugate of claim 1 wherein the therapeutic compound is a peptide or protein [and the peptide is] selected from the group consisting of: enkephalin, adrenocorticotrophic hormone, adenosine deaminase ribonuclease, alkaline phosphatase, angiotensin, antibodies, arginase, arginine deaminase, asparaginase, caerulein, calcitonin, chemotrypsin, cholecystokinin, clotting factors, dynorphins, endorphins, endorphins, enkephalins, ~~enkephalins~~, erythropoietin, gastrin-releasing peptide, glucagon, hemoglobin, hypothalamic releasing factors, interferon, katacalcin, motilin, neuropeptide Y, neurotensin, non-naturally occurring opioids, oxytosin, papain, parathyroid hormone, peptides prolactin, soluble CD-4, somatomedin, somatostatin, somatostatin, somatotropin, superoxide dismutase, thyroid stimulating hormone, tissue plasminogen activator, trypsin, vasopressin and analogues and active fragments thereof.
6. (amended) The amphiphilic drug-oligomer conjugate of claim 1 wherein the therapeutic compound is an [Opioid] opioid receptor agonist, antagonist or partial agonist/partial antagonist.
- aa2
10. (amended) The [The] amphiphilic drug-oligomer conjugate of claim 1 wherein the lipophilic moiety is coupled to the hydrophilic moiety by a bond selected from the group consisting of: amide bond, carbamate bond, carbonate bond and ester bond.
11. (amended) The amphiphilic drug-oligomer conjugate of claim 1 wherein the oligomer moiety is coupled to the drug moiety by a bond selected from the group consisting of amide bond, carbamate bond, carbonate bond, and ester bond.


13. (amended) The amphiphilic drug-oligomer conjugate of claim 1 wherein the hydrophilic moiety is selected from the group consisting of sugars [or] and PEG<sub>1-7</sub>.
14. (amended) The amphiphilic drug-oligomer conjugate of claim 1 wherein the hydrophilic moiety comprises a sugar and the sugar is selected from the group consisting of: amino sugars [and non-amino sugars].
15. (amended) The amphiphilic drug-oligomer conjugate of claim 1 wherein the oligomer is selected from the group consisting of:




wherein n=3 to 25 and m=1 to 6;



wherein n=3 to 25 and m=1 to 7;




wherein n=3 to 25, m=1 to 7 and X=O or N;




wherein m=0 to 5 and R=cholesterol or adamantane; [or]



wherein m=0 to 5;




wherein  $m=0$  to 7; and




(Formula 7)[;].

wherein  $m=1$  to 7 and  $X=\text{N}$  or  $\text{O}$ .


16. (amended) The [method] amphiphilic drug-oligomer conjugate of claim 1 wherein the hydrophilic moiety comprises a sugar and the sugar is selected from the group consisting of [amino sugars and] non-amino sugars.
17. (amended) The [method] amphiphilic drug-oligomer conjugate of claim 1 wherein the hydrophilic moiety comprises a monosaccharide.
18. (amended) [An] The amphiphilic drug-oligomer conjugate of claim 1 wherein the oligomer is selected from the group consisting of:




where  $m=1$  to 7;



where  $m=1$  to 7;










where  $m=1$  to 6;



where  $m=1$  to 6;

where  $m=1$  to 6;




QAS  
cont

0943076 "JUL 1964"

where m=1 to 6;



where m=1 to 6;



where m=1 to 6;




where m=1 to 7;




where m=1 to 7;



where m=1 to 6;








where m=1 to 6; and




where m=1 to 6.

20. (amended) An amphiphilic oligomer-enkephalin conjugate selected from the group consisting of:



[, and]



66620T" SE 20E460

aa4  
conc


24. (amended) The method of claim [18] 23 further characterized in that said conjugate exhibits activity in the without cleavage of the therapeutic compound from the oligomer.
25. (amended) The method of claim [18] 23 wherein the receptor is a G-protein coupled receptor.
26. (amended) The method of claim [18] 23 wherein the receptor is an [Opioid] opiod receptor.
27. (amended) The method of claim [18] 23 wherein the receptor is a [Opioid] opiod receptor; selected from the group consisting of  $\delta$ ,  $\mu$ , and  $\kappa$  receptors.
28. (amended) The method of claim [18] 23 wherein the hydrophilic moiety is selected from the group consisting of sugar and PEG<sub>1-7</sub>.
29. (amended) The method of claim [18] 23 wherein the hydrophilic moiety is selected from the group consisting of fatty acid, alkyl 1-26, cholesterol and adamantane.
30. (amended) The method of claim [18] 23 wherein the therapeutic compound is a peptide having an added N-terminal residue selected from the group consisting of proline[,] and alanine.
31. (amended) The method of claim [18] 23 wherein the therapeutic compound is a peptide or protein.
32. (amended) The method of claim [18] 23 wherein the therapeutic compound is a peptide [and the peptide is] or protein selected from the group consisting of: enkephalin, adrenocorticotrophic hormone, adenosine deaminase ribonuclease, alkaline phosphatase, angiotensin, antibodies, arginase, arginine deaminease, asparaginase, caerulein, calcitonin, chemotrypsin, cholecystokinin, clotting factors, dynorphins, endorphins,

endorphins, enkephalins, erythropoietin, gastrin-releasing peptide, glucagon, hemoglobin, hypothalamic releasing factors, interferon, katacalcin, motilin, neuropeptide Y, neurotensin, non-naturally occurring opioids, oxytosin, papain, parathyroid hormone, peptides prolactin, soluble CD-4, somatomedin, somatostatin, somatostatin, somatotropin, superoxide dismutase, thyroid stimulating hormone, tissue plasminogen activator, trypsin, vasopressin, and analogues and active fragments of such peptides.

33. (amended) The method of claim [18] 23 wherein the amphiphilic oligomer is selected from the group consisting of:



wherein  $n=3$  to  $25$  and  $m=1$  to  $6$ ;



wherein  $n=3$  to  $25$  and  $m=1$  to  $7$ ;




wherein  $n=3$  to  $25$ ,  $m=1$  to  $7$  and  $\text{X}=\text{O}$  or  $\text{N}$ ;



wherein  $m=0$  to  $5$  and  $\text{R}=\text{cholesterol}$  or  $\text{adamantane}$ ; or



wherein  $m=0$  to  $5$ ;





wherein  $m=0$  to 7; and




wherein  $m=1$  to 7 and  $X=\text{N}$  or  $\text{O}$ .

- aa5  
done
34. (amended) The method of claim [18] 23 wherein the hydrophilic moiety is coupled to the hydrophobic moiety by a hydrolyzable bond.
35. (amended) The method of claim [18] 23 wherein the hydrophilic moiety is coupled to the hydrophobic moiety by a non-hydrolyzable bond
- 
37. (amended) The method of claim [31] 36 wherein the therapeutic compound is a peptide or protein.
38. (amended) The method of claim [31] 36 wherein the therapeutic compound is a peptide [and the peptide is] or protein selected from the group consisting of: enkephalin, adrenocorticotrophic hormone, adenosine deaminase ribonuclease, alkaline phosphatase, angiotensin, antibodies, arginase, arginine deaminase, asparaginase, caerulein, calcitonin, chemotrypsin, cholecystokinin, clotting factors, dynorphins, endorphins, endorphins, enkephalins, enkephalins, erythropoietin, gastrin-releasing peptide, glucagon, hemoglobin, hypothalamic releasing factors, interferon, katalcalcin, motilin, neuropeptide Y, neurotensin, non-naturally occurring opioids, oxytosin, papain, parathyroid hormone, peptides prolactin, soluble CD-4, somatomedin, somatostatin, somatostatin, somatotropin, superoxide dismutase, thyroid stimulating hormone, tissue plasminogen activator, trypsin, vasopressin, and analogues and active fragments of such peptides.
39. (amended) The method of claim [31] 36 wherein the therapeutic compound is [met<sup>5</sup>] enkephalin.
40. (amended) The method of claim [31] 36 wherein the lipophilic moiety is coupled to the hydrophilic moiety by a hydrolyzable bond.


556207 SE 20E460

41. (amended) The method of claim [31] 36 wherein the lipophilic moiety is coupled to the hydrophilic moiety by a non-hydrolyzable bond.
42. (amended) The method of claim [31] 36 wherein the lipophilic moiety is coupled to the hydrophilic moiety by a bond selected from the group consisting of: amide bond, carbamate bond, carbonate bond and ester bond.
43. (amended) The method of claim [31] 36 wherein the oligomer moiety is coupled to the drug moiety by a bond selected from the group consisting of amide bond, carbonate bond, carbamate bond, and ester bond.
44. (amended) The method of claim [31] 36 wherein the lipophilic moiety is selected from the group consisting of fatty acids, C<sub>1-26</sub>alkyls, and cholesterol.
45. (amended) The method of claim [31] 36 wherein the hydrophilic moiety is selected from the group [cobsisting] consisting of sugars, and PEG<sub>1-7</sub>.
- 
47. (amended) The method of claim [41] 46 wherein the therapeutic compound is [met<sup>5</sup>]enkephalin.
48. (amended) The method of claim [41] 46 wherein the lipophilic moiety is selected from the group consisting of fatty acids, C<sub>1-26</sub> alkyls, and cholesterol.
49. (amended) The method of claim [41] 46 wherein the one or more hydrophilic moieties are selected from the group consisting of sugars and PEG.
50. (amended) The method of claim [41] 46 wherein the hydrophilic moiety comprises a sugar and the sugar is selected from the group consisting of amino sugars and non-amino sugars.
51. (amended) The method of claim [41] 46 wherein the oligomer is selected from the group consisting of:




(Formula 1)[;],

wherein  $n=3$  to 25 and  $m=1$  to 6;




(Formula 2)[;],

wherein  $n=3$  to 25 and  $m=1$  to 7;




(Formula 3)[;],

wherein  $n=3$  to 25,  $m=1$  to 7 and  $X=\text{O}$  or  $\text{N}$ ;




(Formula 4),

wherein  $m=0$  to 5 and  $\text{R}=\text{cholesterol}$  or  $\text{adamantane}$ ; or



(Formula 5)[;],

wherein  $m=0$  to 4 and  $\text{R}=\text{cholesterol}$  or  $\text{adamantane}$ ;



(Formula 6)[;],






wherein  $m=0$  to 7; and




(Formula 7)[;],

wherein  $m=1$  to 7 and  $X=\text{N}$  or  $\text{O}$ .

52. (amended) The method of claim 46 wherein the [An] amphiphilic oligomer-enkephalin conjugate is selected from the group consisting of:



and




53. (amended) A method for altering the binding affinity of a peptide or protein to its receptor comprising conjugating the peptide to an amphiphilic oligomer comprising a lipophilic moiety coupled to a hydrophilic moiety.

54. (amended) The method according to claim 53 [48 further characterized in that] wherein the binding affinity is increased.
55. (amended) The method according to claim [48 further characterized in that] 53 wherein the binding affinity is reduced.
56. (amended) The method of claim [48] 53 wherein the [peptide is a] peptide or protein is an enkephalin.
57. (amended) The method of claim [48] 56 wherein the peptide or protein is selected from the group consisting of: enkephalin, adrenocorticotrophic hormone, adenosine deaminase ribonuclease, alkaline phosphatase, angiotensin, antibodies, arginase, arginine deaminase, asparaginase, caerulein, calcitonin, chemotrypsin, cholecystokinin, clotting factors, dynorphins, endorphins, endorphins, enkephalins, enkephalins, erythropoietin, gastrin-releasing peptide, glucagon, hemoglobin, hypothalamic releasing factors, interferon, katacalcin, motilin, neuropeptide Y, neurotensin, non-naturally occurring opioids, oxytosin, papain, parathyroid hormone, peptides prolactin, soluble CD-4, somatomedin, somatostatin, somatostatin, somatotropin, superoxide dismutase, thyroid stimulating hormone, tissue plasminogen activator, trypsin, vasopressin, and analogues and fragments of such peptides.
58. (amended) The method of claim [48] 56 wherein the [peptides] peptide is [met<sup>5</sup>]enkephalin.
59. (amended) The method of claim [48] 53 wherein the lipophilic moiety is selected from the group consisting of fatty acids, C<sub>1-26</sub>alkyls, and cholesterol.
60. (amended) The method of claim [48] 53 wherein the hydrophilic moiety is selected from the group consisting of sugars or PEG<sub>1-7</sub>.

61. (amended) The method of claim [48] 53 wherein the oligomer is selected from the group consisting of:



wherein  $n=3$  to 25 and  $m=1$  to 6;



wherein  $n=3$  to 25 and  $m=1$  to 7;




wherein  $n=3$  to 25,  $m=1$  to 7 and  $X=\text{O}$  or  $\text{N}$ ;




wherein  $m=0$  to 5 and  $\text{R}=\text{cholesterol}$  or  $\text{adamantane}$ ; or



wherein  $m=0$  to 5;



wherein  $m=0$  to 7; and



wherein  $m=1$  to 7 and  $X=\text{N}$  or  $\text{O}$ .

62. (amended) The amphiphilic drug-oligomer conjugate of claim 1 wherein the therapeutic compound is a peptide [and the peptide is] selected from the group consisting of:

Ac-Phe-Arg-Trp-Trp-Tyr-Lys—NH<sub>2</sub>;

Ac-Arg-Trp-Ile-Gly-Trp-Lys—NH<sub>2</sub>;

Trp-Trp-Pro-Lys-His-Xaa—NH<sub>2</sub>,

wherein Xaa is a naturally-occurring amino acid;

Trp-Trp-Pro-Xaa—NH<sub>2</sub>,

wherein Xaa is Lys or Arg;

Tyr-Pro-Phe-Gly-Phe-Xaa—NH<sub>2</sub>,

wherein Xaa is a naturally-occurring amino acid;

(D)Ile-(D)Met-(D)Ser-(D)Trp-(D)Trp-Gly<sub>n</sub>-Xaa—NH<sub>2</sub>,

wherein n is 0 or 1 and wherein Xaa is Gly or the D-form of a naturally-occurring amino acid;

(D)Ile-(D)Met-(D)Thr-(D)Trp-Gly-Xaa—NH<sub>2</sub>,

wherein Xaa is Gly or the D-form of a naturally-occurring amino acid;

Tyr-A1-B2-C3—NH<sub>2</sub>,

wherein A1 is (D)Nve or (D)Nle,

B2 is Gly, Phe, or Trp, and

C3 is Trp or Nap;

Pm and red  $\{Me_xH_y-Tyr-(NMe)_z-Tyr-Xaa_z-NH_2\}$ ,

x is 0, 1, or 2,

y is 0, 1, or 2, and

z is 0 or 1, and

wherein Xaa is Phe, (D)Phe, or NHBzl, with the proviso that x and y together is never greater than 2; and

Trp-Trp-Pro-D4-His<sub>z</sub>-Xaa<sub>z</sub>-NH<sub>2</sub>;

wherein z is 0 or 1,

wherein D4 is Lys or Arg, and

wherein Xaa is a naturally-occurring amino acid.

63. (amended) The method of claim 18 wherein the therapeutic compound is a peptide [and the peptide is] selected from the group consisting of:

Ac-Phe-Arg-Trp-Trp-Tyr-Lys-NH<sub>2</sub>,

Ac-Arg-Trp-Ile-Gly-Trp-Lys-NH<sub>2</sub>,

Trp-Trp-Pro-Lys-His-Xaa-NH<sub>2</sub>,

wherein Xaa is a naturally-occurring amino acid;

Trp-Trp-Pro-Xaa-NH<sub>2</sub>,



wherein Xaa is Lys or Arg;

Tyr-Pro-Phe-Gly-Phe-Xaa—NH<sub>2</sub>,

wherein Xaa is a naturally-occurring amino acid;

(D)Ile-(D)Met-(D)Ser-(D)Trp-(D)Trp-Gly<sub>n</sub>-Xaa—NH<sub>2</sub>,

wherein n is 0 or 1 and wherein Xaa is Gly or the D-form of a naturally-occurring amino acid;

(D)Ile-(D)Met-(D)Thr-(D)Trp-Gly-Xaa—NH<sub>2</sub>,

wherein Xaa is Gly or the D-form of a naturally-occurring amino acid;

Tyr-A1-B2-C3—NH<sub>2</sub>,

wherein A1 is (D)Nve or (D)Nle,

B2 is Gly, Phe, or Trp, and

C3 is Trp or Nap;

Pm and red {Me<sub>x</sub>H<sub>y</sub>-Tyr-(NMe)<sub>z</sub>-Tyr-Xaa<sub>z</sub>—NH<sub>2</sub>} ,

x is 0, 1, or 2,

y is 0, 1, or 2, and

z is 0 or 1, and

wherein Xaa is Phe, (D)Phe, or NHBzl, with the proviso that x and y together is never greater than 2;

Trp-Trp-Pro-D4-His<sub>z</sub>-Xaa<sub>z</sub>-NH<sub>2</sub>,

wherein z is 0 or 1,

wherein D4 is Lys or Arg, and

wherein Xaa is a naturally-occurring amino acid.

Please add the following new claims 64 to 72.

64. The amphiphilic drug-oligomer conjugate of claim 1, wherein the therapeutic compound is an opioid.

65. The amphiphilic drug-oligomer conjugate of claim 1, wherein the therapeutic compound is an enkephalin.

66. The method of claim 23 wherein the therapeutic compound is an opioid receptor agonist, antagonist or partial agonist/partial antagonist.

67. The method of claim 23 wherein the therapeutic compound is an enkephalin.

68. The method of claim 36 wherein the therapeutic compound is an opioid receptor agonist, antagonist or partial agonist/partial antagonist.

69. The method of claim 36 wherein the therapeutic compound is an enkephalin.

70. The method of claim 46 wherein the therapeutic compound is an opioid.